

1 Lower Omega-3 Status Associated with Higher Erythrocyte Distribution Width and Neutrophil-
2 Lymphocyte Ratio in UK Biobank Cohort

3 Michael I. McBurney¹⁻³, Nathan L. Tintle^{1,4}, William S. Harris^{1,5}

4 ¹Fatty Acid Research Institute, Sioux Falls, SD 57106, USA (MIM, NLT, WSH); ²Department of Human
5 Health and Nutritional Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada (MIM), ³Division of
6 Biochemical and Molecular Biology, Friedman School of Nutrition Science and Policy, Tufts University,
7 Boston, MA 02111, USA (MIM); ⁴Department of Population Health Nursing Science, College of Nursing,
8 University of Illinois – Chicago, Chicago, IL 60612, USA(NLT); ⁵Sanford School of Medicine, University of
9 South Dakota, Sioux Falls, SD 57105, USA (WSH).

10 **Authors last names:** McBurney, Tintle, Harris

11 **Corresponding author:** M.I. McBurney, Fatty Acid Research Institute, Sioux Falls, SD 57106, USA. E-mail:

12 mim@faresinst.com

13 **Reprint requests:** W.S. Harris, Fatty Acid Research Institute, Sioux Falls, SD 57106, USA. E-mail:

14 wsh@faresinst.com

15 **Sources of Support:** This work was supported by the Fatty Acid Research Institute (FARI). FARI is a non-
16 profit foundation bringing together nutrition scientists and biostatistical experts to accelerate discovery
17 of the relationships between fatty acids, especially omega-3 fatty acids, and health. Analytic code will be
18 made available upon request to the Fatty Acid Research Institute (<https://www.faresinst.org/>).

19 Running Title: Omega-3 Fatty Acids and Hematological Indices

20 **Abbreviations:** BMI, body mass index; CRP, high-sensitivity C-reactive protein; DHA, docosahexaenoic
21 acid; eO3I, estimated omega-3 index; EPA, eicosapentaenoic acid; Hb, hemoglobin; Omega3%, total
22 omega-3 fatty acid; NLR, neutrophil-lymphocyte ratio; O3I, omega-3 index; NMR, nuclear magnetic
23 resonance; RDW, red blood cell distribution width.

24

25 **Abstract**

26 High red blood distribution width (RDW) is associated with decreased red blood cell deformability, and
27 high neutrophil-lymphocyte ratio (NLR) is a biomarker of systemic inflammation and innate-adaptive
28 immune system imbalance. Both RDW and NLR are predictors of chronic disease risk and mortality.
29 Omega-3 index (O3I) values have previously been shown to be inversely associated with RDW and NLR
30 levels. Our objective was to determine if total plasma long chain omega-3 fatty acids (Omega3%)
31 measured in the UK Biobank cohort were associated with RDW and NLR values. RDW- and NLR-
32 relationships with Omega3% were characterized in 109,191 adults (58.4% female). RDW- and NLR-
33 Omega3% relationships were inversely associated with Omega3% (both $p < 0.0001$). These cross-sectional
34 associations confirm previous findings that increasing RDW and NLR values are associated with low O3I.
35 The hypothesis that RDW and/or NLR values can be reduced in individuals with less-than optimal long
36 chain omega 3 values need to be tested in randomized controlled intervention trials using EPA and/or
37 DHA.

38
39 **Keywords:** erythrocytes, neutrophil-lymphocyte ratio, red blood cell distribution width, long chain
40 omega-3 fatty acids.

41

42 Introduction

43 A complete blood count is a routine component of medical exams that provides comprehensive
44 hematologic information. Using standardized reference ranges, healthy individuals can be distinguished
45 from those with nutrient deficiencies, infections, tissue damage, and inflammation. In addition to basic
46 information provided by hemoglobin, hematocrit, and platelet and white blood cell counts, the red
47 blood cell distribution width (RDW) is routinely used to diagnose anemias [1] and may be useful to
48 assess overall wellness [2]. Another metric, the neutrophil-to-lymphocyte ratio (NLR), a measure of
49 innate-adaptive immune balance, is used to monitor inflammation and immunity [3–6]. Risk of non-
50 communicable disease and mortality has been associated with elevated RDW (**Table 1**) and NLR values
51 (**Table 2**).

52 The long-chain omega-3 fatty acid (Omega3%) composition of all cell membranes (including blood
53 cells) affects physicochemical properties such as fluidity, membrane protein function, signaling cascades,
54 overall cell function and ultimately, host physiology [7–9]. The EPA DHA content of RBC membranes, i.e.,
55 the Omega-3 Index (O3I) [10], reflects long-term dietary omega-3 intake [11] and the EPA+DHA
56 composition of major organs [12]. Optimal O3I levels for cardiovascular health appear to be >8% [13].
57 O3I is predictive of risk of total mortality in individuals without prevalent cardiovascular disease [14] and
58 associated with mortality risk before and after adjustment for individual n-6 fatty acids, whether in
59 aggregate, by carbon-chain groups, or individually [15]. A harmonized, de novo analysis of over 42,000
60 individuals prospectively followed for over 16 years, with over 15,000 deaths observed, found risk for
61 total mortality was 15-18% lower in the highest vs lowest quintile for long chain omega-3 fatty acids and
62 similar relationships were observed for death from cardiovascular disease and cancer [16]. Increased
63 dietary long chain omega-3 fatty acid intake increases red blood cell deformability [17–20], and frequent
64 fish consumption is associated with lower NLR [21].

65 In previous studies using a clinical US laboratory database, a low O3I was inversely associated with
66 RDW [22] and NLR [23]. The present study aims to confirm reported RDW and NLR relationships with
67 Omega3% in a large and well-characterized cohort from the UK.

68 **Methods**

69 *Sample:*

70 The UK Biobank is a prospective, population-based cohort of 502,639 individuals, aged 40-69y,
71 recruited between April 2007 and December 2010 [24,25]. Total long chain omega-3 fatty acids
72 (Omega3%) and DHA (DHA%) were measured in plasma as a percent of total fatty acids by nuclear
73 magnetic resonance (NMR, Nightingale Health Plc, Helsinki, Finland) [26] at enrollment. Within the
74 cohort, 117,351 adults ≥ 18 y had data available for Omega3% and DHA%, and 109,191 also had complete
75 data on RDW, neutrophil count, lymphocyte count, NLR, age, sex, body mass index (BMI), high-
76 sensitivity C-reactive protein (CRP), and hemoglobin (Hb) (**Figure 1**). Since O3I was not measured in the
77 UK Biobank, the O3I was calculated from Omega3% using the method of Schuchardt et al [27]. UK
78 Biobank has ethical approval (Ref. 11/NW/0382) from the Northwest Multi-centre Research Ethics
79 Committee as a Research Tissue Bank (RTB). All participants gave electronic signed informed consent.
80 The UK Biobank study was conducted according to the guidelines laid down in the Declaration of
81 Helsinki. The UK Biobank protocol is available online (<http://www.ukbiobank.ac.uk/wp114>
82 [content/uploads/2011/11/UK-Biobank-Protocol.pdf](http://www.ukbiobank.ac.uk/wp114/content/uploads/2011/11/UK-Biobank-Protocol.pdf)). The University of South Dakota Institutional
83 Review Board reviewed and approved the use of de-identified data for research purposes (IRB-21-147).

84 *Statistical methods*

85 Sample characteristics are summarized using standard statistical methods (e.g., means, SDs,
86 correlations) with t-tests. Unadjusted linear models (Model 1) were used to predict RDW and NLR values
87 by cubic splines of Omega3% and DHA%. Model 2 adjusted for sex, age, BMI, CRP and Hb values for

88 RDW and for sex, age, BMI, and CRP for NLR. Pearson correlations were used to assess the strength and
89 direction of linear association between covariates and RDW or NLR. Statistical significance was set to
90 0.05 for all analyses and 95% confidence bands are provided where appropriate.

91

92 **Results**

93 Dietary determinants of Omega3% status have been published for the UK Biobank cohort [27].

94 Thirty-one percent of participants reported using fish oil supplements, and fatty fish were consumed by
95 56% of the cohort, factors contributing to a mean Omega3% of 4.42% (**Table 3**) and O3I = 5.59% [27]. In

96 this cohort of 109,191 individuals, the correlation between Omega3% and DHA% was $r=0.88$. Because

97 Omega3% and DHA% were so highly correlated, only the Omega3% results for Model 1 are presented in

98 the main text, with results for DHA% located in **Supplemental Figure 1**. Model 2 results for RDW- and

99 NLR-relationships with Omega3% and DHA% are also located in **Supplemental Figures 2 and 3**,

100 respectively.

101 RDW was significantly ($p<0.0001$) and inversely associated with Omega3% (**Figure 2A**). Adjustments

102 for age, sex, BMI, CRP and Hb (Model 2) did not significantly change the R^2 nor the shape of the

103 relationship (**Supplemental Figure 2**). Excluding 3,698 individuals with anemia (mean cell volume >100 fL

104 and/or Hb <13 g/dL for males and Hb <12 g/dL for females) as done by [22], did not significantly change

105 the R^2 for the RDW-Omega3% (data not presented).

106 NLR was significantly ($p<0.0001$) and inversely associated with Omega3% (**Figure 3A**). Adjustments

107 for age, sex, BMI and CRP (Model 2) did not significantly change the R^2 nor the shape of the relationship

108 (**Supplemental Figure 2**). Excluding 24,559 individuals with evidence of inflammation, i.e., CRP >3 mg/L,

109 as done by [23], did not significantly change NLR-Omega3% (data not presented).

110

111

112 Discussion

113 In this study examining the UK Biobank cohort, we confirm previously reported inverse associations
114 of long chain omega-3 fatty acid concentrations with RDW [22] (**Figure 2**) and NLR [23] (**Figure 3**). The
115 average estimated O3I of 5.59% in the UK Biobank cohort [27] is similar to that (~5.0%) reported in
116 healthy individuals globally [28,29]. The average RDW in the UK Biobank cohort (13.5%) is similar to
117 values (12.6-12.9%) reported in adults living in the US [30], including those free of cardiovascular disease
118 (NHANES 1994-2004) [31] and without clinical evidence of anemia or inflammation [22]. The UK Biobank
119 average NLR (2.36 ± 1.20 , **Table 3**) is similar to the ~2.2 of the US population [3,6] and a healthy cohort
120 without evidence of anemia or inflammation [23].

121 Elevated RDW levels predict risk for several adverse health outcomes including death (**Table 1**). In
122 four studies of apparently healthy, free-living individuals, the highest RDW category (Cn; top 20-25% of
123 individuals) has an average HR=1.17 (vs C1) (**Table 4**). Thus, the observed distribution of mean RDW
124 values across values of the Omega3% ($13.85-13.40=0.45$ units) (**Figure 2A**) corresponds to a HR = 1.06 or
125 a 6% increased risk of all-cause mortality associated with Omega3% when moving from the highest to
126 lowest observed Omega3% values.

127 An elevated NLR has been associated with increased risk of cardiovascular events, lower respiratory
128 disease, influenza, cancer, and mortality (**Table 2**). In two studies of free living, apparently healthy
129 individuals, the average HR for mortality in the highest NLR category (Cn; top 20-25% of individuals) vs
130 the lowest (C1) NLR (**Table 5**) was 1.43. As shown in Figure 3, there was a 0.7 difference in the mean NLR
131 (1.7 to 2.4) across the observed Omega3% range (**Figure 3A**), which is equivalent to a HR = 1.24 or a 24%
132 increased risk of all-cause mortality associated with Omega3% when moving from the highest to lowest
133 observed Omega3% values.

134 The primary strengths of this study are the large sample of free-living individuals and that blood
135 samples for RDW, NLR, and Omega3% measurements were taken at the same time. Consistent with

136 previous studies (**Figures 2B and 3A**) [22,23], monotonic inverse relationships were observed with long-
137 chain omega-3 concentrations (**Figures 2A and 3A**). The higher RDW and NLR values observed in the UK
138 Biobank cohort may reflect a higher prevalence of inflammation (UKBB mean CRP=2.60±4.40 mg/L vs
139 Health Diagnostic Laboratory mean CRP=1.23± 0.77 mg/L) and differences in age (UKBB mean age
140 =57.1±8.08 y vs Health Diagnostic Laboratory mean = 54.3±14.8 y). Among the limitations are the
141 unavailability of data on levels of other n-3 fatty acids (α -linolenic acid, EPA, and n-3 docosapentaenoic
142 acid) and the potential for other unmeasured (or unconsidered) covariates that might have contributed
143 to the observed associations. The major weakness of this and previous studies [22,23] is their cross-
144 sectional natures which do not provide evidence of causality.

145 In conclusion, significant inverse relationships with RDW- and NLR- were identified with Omega3%
146 and DHA%. These observations in the UK Biobank cohort using a different analytical method, i.e. NMR,
147 confirm previously reported RDW- and NLR relationships with O3I, i.e. EPA+DHA [22,23]. We propose
148 that low Omega3% may indicate a state that is less resilient and/or more predisposed to disease. We
149 cautiously suggest that RDW- and NLR- relationships with Omega3% are clinically relevant and highly
150 recommend that randomized controlled intervention trials using EPA and/or DHA be conducted to
151 determine their effects on RDW and/or NLR values, particularly in individuals with less-than optimal long
152 chain omega 3 values at baseline.

153

154 **CRedit authorship contribution statement: Michael I. McBurney:** Conceptualization, Writing – original
155 draft, Writing – review & editing. **Nathan L. Tintle:** Formal analysis, Writing -reviewing & editing.

156 **William S. Harris:** Conceptualization, Funding acquisition, Writing – review & editing.

157

158 **Disclosures:** M.I. McBurney has or has held consulting agreements in the past 3 years with the Council
159 for Responsible Nutrition; Church & Dwight; DSM Nutritional Products; International Life Sciences

160 Institute, North America; McCormick; PepsiCo; Smartech Topicals; and VitaMe Technologies. W.S. Harris
161 holds an interest in OmegaQuant Analytics, a lab that offers omega-3 blood testing; and is a member of
162 the RB Schiff Science and Innovation Advisory Board. N.L. Tintle has no conflicts to disclose.

163

164

165 **Citations**

- 166 [1] J.D. Bessman, P.R. Gilmer, F.H. Gardner, Improved Classification of Anemias by MCV and RDW, *Am*
167 *J Clin Pathol.* 80 (1983) 322–326. <https://doi.org/10.1093/ajcp/80.3.322>.
- 168 [2] L.C. Pilling, J.L. Atkins, M.O. Duff, R.N. Beaumont, S.E. Jones, J. Tyrrell, C.-L. Kuo, K.S. Ruth, M.A.
169 Tuke, H. Yaghootkar, A.R. Wood, A. Murray, M.N. Weedon, L.W. Harries, G.A. Kuchel, L. Ferrucci,
170 T.M. Frayling, D. Melzer, Red blood cell distribution width: Genetic evidence for aging pathways in
171 116,666 volunteers, *PLoS ONE.* 12 (2017) e0185083.
172 <https://doi.org/10.1371/journal.pone.0185083>.
- 173 [3] B. Azab, M. Camacho-Rivera, E. Taioli, Average Values and Racial Differences of Neutrophil
174 Lymphocyte Ratio among a Nationally Representative Sample of United States Subjects, *PLoS ONE.*
175 9 (2014) e112361. <https://doi.org/10.1371/journal.pone.0112361>.
- 176 [4] J. Li, Q. Chen, X. Luo, J. Hong, K. Pan, X. Lin, X. Liu, L. Zhou, H. Wang, Y. Xu, H. Li, C. Duan,
177 Neutrophil-to-lymphocyte ratio positively correlates to age in healthy population, *J. Clin. Lab. Anal.*
178 29 (2015) 437–443. <https://doi.org/10.1002/jcla.21791>.
- 179 [5] A.M. Paul, S.D. Mhatre, E. Cekanaviciute, A.-S. Schreurs, C.G.T. Tahimic, R.K. Globus, S. Anand, B.E.
180 Crucian, S. Bhattacharya, Neutrophil-to-lymphocyte ratio: A biomarker to monitor the immune
181 status of astronauts, *Front. Immunol.* 11 (2020) 564950.
182 <https://doi.org/10.3389/fimmu.2020.564950>.
- 183 [6] M. Song, B.I. Graubard, C.S. Rabkin, E.A. Engels, Neutrophil-to-lymphocyte ratio and mortality in
184 the United States general population, *Nature Res.* 11 (2021) 464. [https://doi.org/10.1038/s41598-](https://doi.org/10.1038/s41598-020-79431-7)
185 [020-79431-7](https://doi.org/10.1038/s41598-020-79431-7).
- 186 [7] T. Huber, K. Rajamoorthi, V.F. Kurze, K. Beyer, M.F. Brown, Structure of Docosahexaenoic Acid-
187 Containing Phospholipid Bilayers as Studied by 2H NMR and Molecular Dynamics Simulations, *J.*
188 *Am. Chem. Soc.* 124 (2002) 298–309. <https://doi.org/10.1021/ja011383j>.

- 189 [8] H.F. Turk, R.S. Chapkin, Membrane lipid raft organization is uniquely modified by n-3
190 polyunsaturated fatty acids, *PLEFA*. 88 (2013) 43–47.
- 191 [9] P.C. Calder, Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and
192 clinical relevance, *Bioch. Biophys. Acta: Mol Cell Biol Lipids*. 1851 (2015) 469–484.
193 <https://doi.org/10.1016/j.bbalip.2014.08.010>.
- 194 [10] W.S. Harris, C. von Schacky, The Omega-3 Index: a new risk factor for death from coronary heart
195 disease?, *Prev. Med.* 39 (2004) 212–220. <https://doi.org/10.1016/j.ypmed.2004.02.030>.
- 196 [11] K.H. Jackson, J.M. Polreis, N.L. Tintle, P.M. Kris-Etherton, W.S. Harris, Association of reported fish
197 intake and supplementation status with the omega-3 index, *Prostaglandins, Leukotrienes and*
198 *Essential Fatty Acids*. 142 (2019) 4–10. <https://doi.org/10.1016/j.plefa.2019.01.002>.
- 199 [12] J.I. Fenton, E.A. Gutzell, E.A. Davidson, W.S. Harris, Red blood cell PUFAs reflect the phospholipid
200 PUFA composition of major organs, *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 112
201 (2016) 12–23. <https://doi.org/10.1016/j.plefa.2016.06.004>.
- 202 [13] W.S. Harris, The Omega-3 Index: Clinical Utility for Therapeutic Intervention, *Curr Cardiol Rep*. 12
203 (2010) 503–508. <https://doi.org/10.1007/s11886-010-0141-6>.
- 204 [14] M.I. McBurney, N.L. Tintle, R.S. Vasan, A. Sala-Vila, W.S. Harris, Using an erythrocyte fatty acid
205 fingerprint to predict risk of all-cause mortality: the Framingham Offspring Cohort, *The American*
206 *Journal of Clinical Nutrition*. (2021) nqab195. <https://doi.org/10.1093/ajcn/nqab195>.
- 207 [15] W. Harris, N. Tintle, V. Ramachandran, Erythrocyte n-6 fatty acids and risk for cardiovascular
208 outcomes and total mortality in the Framingham Heart Study, *Nutrients*. 10 (2018) 2012.
209 <https://doi.org/10.3390/nu10122012>.
- 210 [16] W.S. Harris, N.L. Tintle, F. Imamura, F. Qian, A.V. Ardisson Korat, M. Marklund, L. Djoussé, J.K.
211 Bassett, P.-H. Carmichael, Y.-Y. Chen, Y. Hirakawa, L.K. Kupers, M. Lankinen, R.A. Murphy, C.
212 Samieri, M.K. Senn, P. Shi, J.K. Virtanen, I.A. Brouwer, K.-L. Chien, G. Eiriksdottir, N.G. Forouhi, J.M.

- 213 Geleijnse, G.G. Giles, V. Gudnason, C. Helmer, A. Hodge, R. Jackson, K.-T. Khaw, M. Laakso, H. Lai,
214 D. Laurin, J. Lindsay, R. Micha, J. Mursu, T. Ninomiya, W. Post, B.M. Psaty, U. Riserus, J.G.
215 Robinson, A.H. Shadyab, L. Snetselaar, A. Sala-Vila, Y. Sun, L.M. Steffen, M.Y. Tsai, N.J. Wareham,
216 A.C. Wood, J.H.Y. Wu, F. Hu, Q. Sun, D.S. Siscovick, R.N. Lemaitre, D. Mozaffarian, F. The Fatty
217 Acids and Outcomes Research Consortium, Blood n-3 fatty acid levels and total and cause-specific
218 mortality from 17 prospective studies, *Nature Commun.* 12 (2021) 1–9.
219 <https://doi.org/10.1038/s41467-021-22370-2>.
- 220 [17] T. Terano, A. Hirai, T. Hamazaki, S. Kobayashi, T. Fujita, Y. Tamura, A. Kumagai, Effect of oral
221 administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and
222 red cell deformability in healthy human subjects, *Atherosclerosis.* 46 (1983) 321–331.
- 223 [18] I.J. Cartwright, A.G. Pockley, J.H. Galloway, M. Greaves, F.E. Preston, The effects of dietary omega-
224 3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability
225 and blood viscosity in healthy volunteers, *Atherosclerosis.* 55 (1985) 267–281.
- 226 [19] R. Bach, U. Schmidt, F. Jung, H. Kiesewetter, B. Hennen, E. Wenzel, H. Schieffer, L. Bette, S.
227 Heyden, Effects of Fish Oil Capsules in Two Dosages on Blood Pressure, Platelet Functions,
228 Haemorheological and Clinical Chemistry Parameters in Apparently Healthy Subjects, *Ann Nutr*
229 *Metab.* 33 (1989) 359–367. <https://doi.org/10.1159/000177559>.
- 230 [20] E. Hessel, J.J. Agren, M. Paulitschke, O. Hanninen, A. Hanninen, D. Lerche, Freshwater fish diet
231 affects lipid composition, deformability and aggregation properties of erythrocytes,
232 *Atherosclerosis.* 82 (1990) 37–42.
- 233 [21] S. Tani, R. Matsuo, W. Atsumi, K. Kawauchi, T. Ashida, T. Yagi, K. Imatake, Y. Suzuki, A. Takahashi,
234 N. Matsumoto, Y. Okumura, Higher frequency of fish intake may be associated with a lower
235 neutrophil/lymphocyte ratio: Anti-atherosclerotic effects of fish consumption, *Ann Nutr Metab.*
236 (2021) 1–8. <https://doi.org/10.1159/000515915>.

- 237 [22] M.I. McBurney, N.L. Tintle, W.S. Harris, Omega-3 index is directly associated with a healthy red
238 blood cell distribution width, *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 176 (2022)
239 102376. <https://doi.org/10.1016/j.plefa.2021.102376>.
- 240 [23] M.I. McBurney, N.L. Tintle, W.S. Harris, The omega-3 index is inversely associated with the
241 neutrophil-lymphocyte ratio in adults', *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 177
242 (2022) 102397. <https://doi.org/10.1016/j.plefa.2022.102397>.
- 243 [24] C. Sudlow, J. Gallacher, N. Allen, V. Beral, P. Burton, J. Danesh, P. Downey, P. Elliott, J. Green, M.
244 Landray, B. Liu, P. Matthews, G. Ong, J. Pell, A. Silman, A. Young, T. Sprosen, T. Peakman, R. Collins,
245 UK Biobank: An open access resource for identifying the causes of a wide range of complex
246 diseases of middle and old age, *PLoS Med*. 12 (2015) e1001779.
247 <https://doi.org/10.1371/journal.pmed.1001779>.
- 248 [25] H. Julkunen, A. Cichońska, P.E. Slagboom, P. Würtz, Nightingale Health UK Biobank Initiative,
249 Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-
250 19 in the general population, *ELife*. 10 (2021) e63033. <https://doi.org/10.7554/eLife.63033>.
- 251 [26] P. Wurtz, J.R. Raiko, C.G. Magnussen, P. Soininen, A.J. Kangas, T. Tynkkynen, R. Thomson, R.
252 Laatikainen, M.J. Savolainen, J. Laurikka, P. Kuukasjarvi, M. Tarkka, P.J. Karhunen, A. Jula, J.S.
253 Viikari, M. Kahonen, T. Lehtimaki, M. Juonala, M. Ala-Korpela, O.T. Raitakari, High-throughput
254 quantification of circulating metabolites improves prediction of subclinical atherosclerosis,
255 *European Heart Journal*. 33 (2012) 2307–2316. <https://doi.org/10.1093/eurheartj/ehs020>.
- 256 [27] J.P. Schuchardt, N. Tintle, J. Westra, W.S. Harris, Estimation and predictors of the Omega-3 Index in
257 the UK Biobank, *Br J Nutr*. (2022) 1–40. <https://doi.org/10.1017/S0007114522003282>.
- 258 [28] J.P. Schuchardt, M. Cerrato, M. Ceseri, L.F. DeFina, G.E. Delgado, S. Gellert, A. Hahn, B.V. Howard,
259 A. Kadota, M.E. Kleber, R. Latini, W. Maerz, J.E. Manson, S. Mora, Y. Park, A. Sala-Vila, C. von
260 Schacky, A. Sekikawa, N. Tintle, K.L. Tucker, R.S. Vasan, W.S. Harris, Red blood cell fatty acid

- 261 patterns from 7 countries: Focus on the Omega-3 index, Prostaglandins, Leukotrienes and Essential
262 Fatty Acids. 179 (2022) 102418. <https://doi.org/10.1016/j.plefa.2022.102418>.
- 263 [29] K.D. Stark, M.E. Van Elswyk, M.R. Higgins, C.A. Weatherford, N. Salem, Global survey of the omega-
264 3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy
265 adults, *Prog. Lipid Res.* 63 (2016) 132–152. <https://doi.org/10.1016/j.plipres.2016.05.001>.
- 266 [30] J.M. Crook, A.L. Horgas, S.L. Yoon, O. Grundmann, V. Johnson-Mallard, Vitamin C Plasma Levels
267 Associated with Inflammatory Biomarkers, CRP and RDW: Results from the NHANES 2003–2006
268 Surveys, *Nutrients.* 14 (2022) 1254. <https://doi.org/10.3390/nu14061254>.
- 269 [31] V. Veeranna, S.K. Zalawadiya, S. Panaich, K.V. Patel, L. Afonso, Comparative analysis of red cell
270 distribution width and high sensitivity C-reactive protein for coronary heart disease mortality
271 prediction in multi-ethnic population: Findings from the 1999–2004 NHANES, *Int. J. Cardiol.* 168
272 (2013) 5156–5161. <https://doi.org/10.1016/j.ijcard.2013.07.109>.
- 273 [32] Q. Li, X. Chen, B. Han, Red blood cell distribution width is associated with frailty in older inpatients
274 in China: Sex differences in a cross-sectional study, *Experimental Gerontology.* 150 (2021) 111392.
275 <https://doi.org/10.1016/j.exger.2021.111392>.
- 276 [33] E.M. Hald, M.-L. Løchen, J. Lappegård, T.S. Ellingsen, E.B. Mathiesen, T. Wilsgaard, I. Njølstad, S.K.
277 Brækkan, J.-B. Hansen, Red Cell Distribution Width and Risk of Atrial Fibrillation and Subsequent
278 Thromboembolism: The Tromsø Study, *TH Open.* 04 (2020) e280–e287. [https://doi.org/10.1055/s-](https://doi.org/10.1055/s-0040-1716417)
279 [0040-1716417](https://doi.org/10.1055/s-0040-1716417).
- 280 [34] H.-M. Yao, T.-W. Sun, X.-J. Zhang, D.-L. Shen, Y.-Y. Du, Y.-D. Wan, J.-Y. Zhang, L. Li, L.-S. Zhao, Red
281 blood cell distribution width and long-term outcome in patients undergoing percutaneous
282 coronary intervention in the drug-eluting stenting era: A two-year cohort study, *PLoS ONE.* 9
283 (2014) e94887. <https://doi.org/10.1371/journal.pone.0094887>.

- 284 [35] T. Osadnik, J. Strzelczyk, M. Hawranek, A. Lekston, J. Wasilewski, A. Kurek, A.R. Gutowski, K.
285 Wilczek, K. Dyrbuś, M. Gierlotka, A. Wiczowski, M. Gąsior, A. Szafranek, L. Poloński, Red cell
286 distribution width is associated with long-term prognosis in patients with stable coronary artery
287 disease, *BMC Cardiovasc Disord.* 13 (2013) 113. <https://doi.org/10.1186/1471-2261-13-113>.
- 288 [36] S.K. Zalawadiya, V. Veeranna, S.S. Panaich, L. Afonso, J.K. Ghali, Gender and Ethnic Differences in
289 Red Cell Distribution Width and Its Association With Mortality Among Low Risk Healthy United
290 State Adults, *The American Journal of Cardiology.* 109 (2012) 1664–1670.
291 <https://doi.org/10.1016/j.amjcard.2012.01.396>.
- 292 [37] S.K. Zalawadiya, V. Veeranna, S.S. Panaich, L. Afonso, Red cell distribution width and risk of
293 peripheral artery disease: Analysis of National Health and Nutrition Examination Survey 1999–
294 2004, *Vasc Med.* 17 (2012) 155–163. <https://doi.org/10.1177/1358863X12442443>.
- 295 [38] T.S. Perlstein, J. Weuve, M.A. Pfeffer, J.A. Beckman, Red blood cell distribution width and mortality
296 risk in a community-based prospective cohort, *Arch Intern Med.* 169 (2009) 588.
297 <https://doi.org/10.1001/archinternmed.2009.55>.
- 298 [39] K.V. Patel, L. Ferrucci, W.B. Ershler, D.L. Longo, J.M. Guralnik, Red blood cell distribution width and
299 the risk of death in middle-aged and older adults, *Arch Intern Med.* 169 (2009) 515.
300 <https://doi.org/10.1001/archinternmed.2009.11>.
- 301 [40] J. Guo, H. Zhang, Y. Li, M. Hao, G. Shi, J. Wang, Z. Wang, X. Wang, Neutrophil-lymphocyte ratio as a
302 predictor of slow gait speed in older adults: The Rugao Longitudinal Aging Study, *Experimental*
303 *Gerontology.* 152 (2021) 111439. <https://doi.org/10.1016/j.exger.2021.111439>.
- 304 [41] N.H. Adamstein, J.G. MacFadyen, L.M. Rose, R.J. Glynn, A.K. Dey, P. Libby, I.A. Tabas, N.N. Mehta,
305 P.M. Ridker, The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from
306 five contemporary randomized trials, *European Heart Journal.* 42 (2021) 896–903.
307 <https://doi.org/10.1093/eurheartj/ehaa1034>.

- 308 [42] H. Wada, T. Dohi, K. Miyauchi, R. Nishio, M. Takeuchi, N. Takahashi, H. Endo, M. Ogita, H. Iwata, T.
309 Kasai, S. Okazaki, K. Isoda, S. Suwa, H. Daida, Neutrophil to lymphocyte ratio and long-term
310 cardiovascular outcomes in coronary artery disease patients with low high-sensitivity C-reactive
311 protein level, *Int. Heart J.* 61 (2020) 447–453. <https://doi.org/10.1536/ihj.19-543>.
- 312 [43] J.-H. Liu, Y.-J. Zhang, Q.-H. Ma, H.-P. Sun, Y. Xu, C.-W. Pan, Elevated blood neutrophil to
313 lymphocyte ratio in older adults with cognitive impairment, *Archives of Gerontology and*
314 *Geriatrics.* 88 (2020) 104041. <https://doi.org/10.1016/j.archger.2020.104041>.
- 315 [44] J. Fest, T.R. Ruiter, B. Groot Koerkamp, D. Rizopoulos, M.A. Ikram, C.H.J. van Eijck, B.H. Stricker,
316 The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The
317 Rotterdam Study, *Eur J Epidemiol.* 34 (2019) 463–470. [https://doi.org/10.1007/s10654-018-0472-](https://doi.org/10.1007/s10654-018-0472-y)
318 [y](https://doi.org/10.1007/s10654-018-0472-y).
- 319 [45] B. Suh, D.W. Shin, H.-M. Kwon, J.M. Yun, H.-K. Yang, E. Ahn, H. Lee, J.H. Park, B. Cho, Elevated
320 neutrophil to lymphocyte ratio and ischemic stroke risk in generally healthy adults, *PLoS ONE.* 12
321 (2017) e0183706. <https://doi.org/10.1371/journal.pone.0183706>.

322

323

Table 1. Odds Ratio (OR) or Hazards Ratio (HR) per 0.01 unit increase in red blood cell distribution width (RDW) with respect to clinical outcome.

Outcome	Population	Study	n	Quantile of RDW					OR or HR (95% CI)	p-value	Citation
				1	2	3	4	5			
Frailty	Hospitalized men, ≥60y	Comprehensive tertiary hospital in mainland China	334	≤12.6%	12.6-13.1%	13.1-13.7%	>13.7%		OR=1.14 (1.05-1.24)	0.002	[32]
Frailty	Hospitalized women, ≥60y	Comprehensive tertiary hospital in mainland China	285	≤12.6%	12.6-13.1%	13.1-13.7%	>13.7%		OR=1.27 (1.16-1.38)	<0.001	[32]
Incident atrial fibrillation (AF)	Adults ≥25y	inhabitants of Tromso, Norway	26,111	<12.3%	12.4-12.7%	12.8-13.2%	≥13.3%		HR=1.08 (1.03-1.12)	Not reported	[3]
Venous thromboembolism	Adults with AF ≥25y	inhabitants of Tromso, Norway	1,812	<12.7%	12.8-13.3%	>13.3%			HR=1.09 (0.83-1.41)	Not reported	[3]
Ischemic stroke	Adults with AF ≥25y	inhabitants of Tromso, Norway	1,812	<12.7%	12.8-13.3%	>13.3%			HR=1.18 (1.03-1.34)	Not reported	[3]
In-hospital mortality	Patients without anemia who underwent percutaneous coronary intervention (PCI)	Affiliated hospital of Zhengzhou University, China	2,169	<12.27%	12.27-≤13.0%	>13-<13.5%	≥13.5%		HR=1.4 (1.23-1.59)	0.000	[4]
All-cause mortality	Patients with stable coronary artery disease undergoing stent implantation	Silesian Centre for Heart Diseases, Poland	2,033	<13.1%	13.1-<13.6%	13.6-<14.1%	≥14.1%		HR=1.23 (1.13-1.35)	<0.0001	[5]
All deaths, men	Adults ≥20y without diabetes or CV	NHANES 1988-1994, USA	7,201	≤12.4%	>12.4-≤12.9%	>12.9-≤13.5%	>13.5%		HR=1.21 (1.18-1.25)	<0.001	[6]
All deaths, women	Adults ≥20y without diabetes or previous CV	NHANES 1988-1994, USA	8,259	≤12.4%	>12.4-≤12.9%	>12.9-≤13.5%	>13.5%		HR=1.19 (1.14-1.24)	<0.001	[36]
All CV deaths, men	Adults ≥20y without diabetes or previous CV	NHANES 1988-1994, USA	7,201	≤12.4%	>12.4-≤12.9%	>12.9-≤13.5%	>13.5%		HR=1.19 (1.14-1.25)	<0.001	[36]
All CV deaths, women	Adults ≥20y without diabetes or previous CV	NHANES 1988-1994, USA	8,259	≤12.4%	>12.4-≤12.9%	>12.9-≤13.5%	>13.5%		HR=1.19 (1.12-1.26)	<0.001	[36]

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.09.22283290>; this version posted December 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Coronary heart disease (CHD) deaths, men	Adults ≥20y without diabetes or previous CV	NHANES 1988-1994, USA	7,201	≤12.4%	>12.4-≤12.9%	>12.9-≤13.5%	>13.5%		HR=1.20 (1.12-1.28)	<0.001	[36]
CHD deaths, women	Adults ≥20y without diabetes or previous CV	NHANES 1988-1994, USA	8,259	≤12.4%	>12.4-≤12.9%	>12.9-≤13.5%	>13.5%		HR=1.20 (1.11-1.29)	<0.001	[36]
Peripheral artery disease	Adults ≥40y	NHANES 1999-2004, USA	6,950	<12.2%	12.3-12.5%	12.6-13.1%	>13.1%		HR=1.23 (1.14-1.33)	<0.001	[37]
All-cause mortality	Adults ≥40y	NHANES 1988-1994, USA	15,852	<12.35%	12.5-12.65%	12.8-13.15%	13.2-13.75%	≥13.80%	HR=1.27 (1.21-1.33)	<0.001	[38]
CV mortality	Adults ≥40y	NHANES 1988-1994, USA	15,852	<12.35%	12.5-12.65%	12.8-13.15%	13.2-13.75%	≥13.80%	HR=1.26 (1.19-1.33)	<0.001	[38]
Cancer mortality	Adults ≥40y	NHANES 1988-1994, USA	15,582	<12.35%	12.5-12.65%	12.8-13.15%	13.2-13.75%	≥13.80%	HR=1.30 (1.22-1.39)	<0.001	[38]
Chronic lower respiratory tract disease mortality	Adults ≥40y	NHANES 1988-1994, USA	15,582	<12.35%	12.5-12.65%	12.8-13.15%	13.2-13.75%	≥13.80%	HR=1.36 (1.29-1.51)	0.03	[8]
All-cause mortality	Adults ≥45y	NHANES 1988-1994, USA	8,175	<12.55%	12.55-12.95%	13.0-13.4%	13.45-14.05%	>14.05%	HR=1.22 (1.15-1.30)	<0.001	[9]

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.09.22283290>; this version posted December 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).

4
5
6

Table 2. Odds Ratio (OR) or Hazards Ratio (HR) per increase in neutrophil-lymphocyte ratio (NLR) with respect to clinical outcome.

Outcome	Population	Study	n	Quantiles of NLR						OR or HR	p-value	Citation
				1	2	3	4	5	6			
Slow gait	Adults ≥70y	Rugao Longitudinal Aging Study, China	1,753	≤1.29	>1.29-≤1.79	>1.79-≤2.36	>2.36			OR ¹ =2.73 (1.60-4.68)	<0.001	[40]
All-cause mortality	Adults ≥30y	NHANES 1999-2014, USA	32,454	<1.54	1.54-2.00	2.01-2.67	>2.67			HR ² =1.14 (1.10-1.17)	<0.0001	[6]
Heart disease mortality	Adults ≥30y	NHANES 1999-2014, USA	900	<1.54	1.54-2.00	2.01-2.67	>2.67			HR ² =1.17 (1.06-1.29)	0.002	[6]
Chronic lower respiratory disease mortality	Adults ≥30y	NHANES 1999-2014, USA	197	<1.54	1.54-2.00	2.01-2.67	>2.67			HR ² =1.24 (1.04-1.47)	0.02	[6]
Influenza/pneumonia mortality	Adults ≥30y	NHANES 1999-2014, USA	82	<1.54	1.54-2.00	2.01-2.67	>2.67			HR ² =1.26 (1.03-1.54)	0.03	[6]
Kidney disease mortality	Adults ≥30y	NHANES 1999-2014, USA	89	<1.54	1.54-2.00	2.01-2.67	>2.67			HR ² =1.62 (1.21-2.17)	0.001	[6]
All-cause mortality in individuals with prior myocardial infarction (MI), CANTOS	Adults with prior myocardial infarction (MI) and CRP ≥2mg/L	Canakinumab Thrombosis Outcomes Study (CANTOS)	10,061	≤1.81	1.81-≤2.36	2.37-≤3.08	>3.08			HR ² = 1.36 (1.30-1.46)	<0.0001	[41]
Cardiovascular (CV) death, CANTOS	Adults with prior myocardial infarction (MI) and CRP ≥2mg/L	Canakinumab Thrombosis Outcomes Study (CANTOS)	10,061	≤1.81	1.81-≤2.36	2.37-≤3.08	>3.08			1.36 ² (1.27-1.46)	<0.0001	[41]
Major adverse cardiovascular event (MACE): non-fatal	Adults with prior myocardial	Canakinumab Thrombosis Outcomes	10,061	≤1.81	1.81-≤2.36	2.37-≤3.08	>3.08			HR ² =1.22 (1.16-1.28)	<0.0001	[41]

MI, non-fatal stroke or CV death	infarction (MI) and CRP ≥ 2 mg/L	Study (CANTOS)											
MACE + hospitalization of unstable angina requiring urgent revascularization (MACE+)	Adults with prior myocardial infarction (MI) and CRP ≥ 2 mg/L	Canakinumab Thrombosis Outcomes Study (CANTOS)	10,061	≤ 1.81	1.81- ≤ 2.36	2.37- ≤ 3.08	> 3.08				HR ² = 1.20 (1.14-1.25)	< 0.0001	[41]
MACE+	Healthy patients with LDL-C < 130 mg/dL and CRP ≥ 2 mg/L	Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)	17,802	≤ 1.58	1.58- ≤ 2.10	2.10- ≤ 2.75	> 2.75				HR ² =1.11 (1.01-1.22)	0.03	[41]
MACE+	Patients with prior CV event and LDL-C ≥ 70 mg/dL	PCSK9 Inhibition and the Reduction of Vascular Events (SPIRE-1)	16,819	≤ 1.72	1.72- ≤ 2.24	2.24- ≤ 2.93	> 2.93				HR ² =1.31 (1.14-1.49)	0.00007	[41]
MACE+	Patients with prior CV event and LDL-C ≥ 100 mg/dL	PCSK9 Inhibition and the Reduction of Vascular Events (SPIRE-2)	10,621	≤ 1.67	1.67- ≤ 2.16	2.16- ≤ 2.83	> 2.83				HR ² =1.27 (1.12-1.43)	0.0002	[41]
MACE+	Patients with previous MI or multi-vessel coronary disease and either type 2 diabetes or metabolic syndrome	Cardiovascular Inflammation Reduction Trial (CIRT)	4,768	≤ 1.73	1.73- ≤ 2.27	2.27- ≤ 2.96	> 2.96				HR ² =1.09 (1.00-1.20)	0.045	[41]

CV events: CV death, non-fatal MI, and non-fatal stroke	Patients with coronary artery disease who underwent elective percutaneous coronary intervention (PCI)	Juntendo University Hospital, Japan	1,951	<1.5	1.5-1.9	1.9-2.5	≥2.5				HR ¹ =1.85 (1.19-2.88)	0.007	[42]
Cognitive impairment	Adults ≥60y, community dwelling	Weitang Geriatric Diseases Study, China	4,579	<1.535	1.535-2.022	2.023-2.641	>2.641				HR ³ =1.11 (1.03-1.20)	0.02	[43]
All-cause mortality	Adults ≥45y, community dwelling	Rotterdam Study, The Netherlands	8,715	<1.30	1.30-1.59	1.60-1.91	1.92-2.41	>2.41			HR ⁴ =1.64 (1.44-1.86)	<0.001	[44]
Ischemic stroke	Adults, 30-75y, undergoing general health screening	Seoul National University Hospital, Korea	24,708	<1.5	1.5-<2.0	2.0-<2.5	2.5-<3.0	3.0-<3.5	>3.5		HR ⁴ =2.96 (1.57-5.58)	<0.001	[45]
¹ per 1 unit increase in logNLR. ² Per category increase in NLR. ³ per SD increase in logNLR. ⁴ comparing highest vs lowest quartile													

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Table 3. Variable distributions (Mean±SD) for entire UK Biobank cohort.

Variable	All ¹	Female	Male ²
n	101,191	59,113	50,078
DHA, %	2.01±0.68	2.12±0.66	1.88±0.68 ³²⁹
Omega3, %	4.42 (1.56)	4.6 (1.58)	4.21 (1.5)
RDW %	13.49±0.98	13.32±1.05	13.45±0.89 ³³⁰
NLR	2.36±1.20	2.26±1.09	2.48±1.31 ³³¹
Neutrophil, 10 ³ /μL	4.22±1.42	4.19±1.40	4.26±1.45
Lymphocyte, 10 ³ /μL	1.96±1.04	2.01±0.89	1.90±1.19 ³³²
Age, y	57.06±8.08	56.89±7.98	57.27±8.19
BMI, kg/m ²	27.42±4.77	27.08±5.15	27.84±4.23 ³³³
CRP, mg/L	2.60±4.40	2.69±4.33	2.49±4.49
Deprivation Score ²	-1.33±3.09	-1.36±3.04	-1.29±3.14 ³³⁴
Hb, g/dL	14.17±1.24	13.49±0.96	14.98±1.03 ³³⁵
¹ Based on self-identified social construct for race: 94.58% White, 0.57% Black, 1.91% Asian, and 2.94% Other.			
² With the exception of number (n), variable means are statistically different between females and males, p<0.0001.			

338

Table 4. Mortality Hazard Ratio (HR) comparing the highest (top 20-25% of individuals) and lowest (bottom 20-25% of individuals) categories in red blood cell distribution width (RDW) in apparently healthy, free-living individuals.

Outcome	Population	Study	n	RDW (%) Cn-C1 ¹	HR (95% CI)	p-value	Citation
Coronary heart disease (CHD) deaths, men	Adults ≥20y without diabetes or previous CV	NHANES 1988-1994, USA	7,201	1.10	1.19 (1.16-1.22)	<0.001	[36]
CHD deaths, women	Adults ≥20y without diabetes or previous CV	NHANES 1988-1994, USA	8,259	1.10	1.17 (1.13, 1.22)	<0.001	[36]
All-cause mortality	Adults ≥40y	NHANES 1988-1994, USA	15,852	1.45	1.18 (1.14, 1.22)	<0.001	[38]
All-cause mortality	Adults ≥45y	NHANES 1988-1994, USA	8,175	1.50	1.14 (1.10, 1.19)	<0.001	[39]
Average				1.29	1.17		

¹ Highest category (Cn) minus lowest C1.

339

340

Table 5. Mortality Hazards Ratio (HR) comparing the highest (top 20-25% of individuals) and lowest categories (bottom 20-25% of individuals) in neutrophil-lymphocyte ratio (NLR).							
Outcome	Population	Study	n	NLR Cn-C1 ¹	HR (95% CI)	p-value	Citation
All-cause mortality	Adults ≥30y	NHANES 1999-2014, USA	32,454	1.4	1.30 (1.21, 1.41)	<0.0001	[6]
All-cause mortality	Adults ≥45y, community dwelling	Rotterdam Study, The Netherlands	8,715	1.11	1.56 (1.39, 1.75)	<0.001	[44]
Average				1.26	1.43		

¹ Highest category (Cn) minus lowest C1.

341

342


343 Figure 1. Analytical sample flow chart. Hb, hemoglobin; NLR, neutrophil-lymphocyte ratio; RDW, red blood cell
344 distribution width; CRP, C-reactive protein.

345



346 Figure 2. A. Unadjusted red blood cell distribution width (RDW) relationship with omega-3 percentage
347 (Omega3%). Omega-3 Index (O3I) values calculated using the conversion equation [O3I = 1.2791*Omega3%+
348 1.0589 (R2=0.59; r=0.77)]. B. Unadjusted RDW relationship with the Omega-3 Index (O3I) adapted from
349 McBurney et al (22).

350

351 Figure 3. A. Unadjusted neutrophil-lymphocyte ratio (NLR) relationship with omega-3 percentage (Omega3%).
352 Omega-3 Index (O3I) values calculated using the conversion equation [O3I = 1.2791*Omega3%+ 1.0589
353 (R2=0.59; r=0.77)]. B. Unadjusted NLR relationship with the Omega-3 Index (O3I) adapted from McBurney et al
354 (23).



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

